Kura Oncology KURA Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Product | ||||||
| Darlifarnib | $28.05M— | $26.71M— | $25.67M— | $22.36M— | —— | |
| Discovery Stage Program | $6.54M-9.7% | $7.23M+9.2% | $6.99M+11.0% | $7.02M+19.4% | $7.24M+31.3% | |
| Ziftomenib | $149.51M+57.7% | $142.58M+79.7% | $134.85M+120% | $113.53M+121% | $94.79M+129% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Kura Oncology break its business down?
- Kura Oncology (KURA) reports revenue by product across 3 parts — Development Services For Monotherapy, Development Services In Combination With Other Therapies and License And Collaboration Revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Kura Oncology's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Kura Oncology's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
